Funding for this research was provided by:
Innovent Biologics, Inc (n/a)
Eli Lilly and Company (n/a)
National Health and Family Planning Commission Research Fund & Zhejiang Provincial Medical and Health major Science and Technology Plan Project (KWJ-ZJ-1802)
Public Welfare Technology Application Research Project of Zhejiang Province (LGF20E030004)
Received: 24 March 2020
Accepted: 3 August 2020
First Online: 14 August 2020
Ethics approval and consent to participate
: The trial protocol was approved by the Institutional Review Boards and Ethical Committee of The First Hospital Affiliated to Zhejiang University School of Medicine and Beijing Cancer Hospital, and the study was carried out strictly following the declaration of Helsinki principles; all participating patients signed consent forms before taking part in the trial. The trial national registration number is NCT02937116.
: Not applicable.
: Hui Zhou, Shuyan Wang, Donglei Zhu, Bo Peng are the staff of Innovent Biologics, Inc., Suzhou, China Suzhou, China. Lin Shen is the associate editor of <i>BMC Cancer.</i> All remaining authors declare that they have no competing interests.